Summary: The binding of drugs to plasma proteins, such as albumin and a1-acid glycoprotein (AGP) is a major determinant in the disposition of drugs. A topology analysis of drug binding sites on HSA and AGP was determined using various methods, including spectroscopy, QSAR, photoa‹nity labeling and site directed mutagenesis. Recombinant albumin was found to be useful for rapidly identifying drug binding sites. The binding sites on AGP are not completely separated but are partially overlapped, and Trp, Tyr, Lys and His residues in the drug binding pockets play important roles in this process. Drug displacement is somewhat complex, due to the involvement of multiple eŠects. The reduced binding in uremic patients may be explained by a mechanism that involves a combination of direct displacement by free fatty acids as well as cascade eŠects of free fatty acids and unbound uremic toxins for signiˆcant inhibition in serum binding. Albumin-containing dialysate is useful for the extracorporeal removal of endogenous toxins and in the treatment of drug overdoses. Oxidized albumin is a useful biomarker for the quantitative and qualitative evaluation of oxidative stress. Interestingly, AGP undergoes a structural transition to a unique structure that diŠers from the native and denatured states, when it interacts with membranes.
Introduction
Many drugs bind reversibly to plasma proteins. Thus, drugs are transported in the circulation, either free, dissolved in the aqueous phase of the plasma, or bound in the form of complex with plasma proteins. Because of this, the binding of drugs to proteins is an important factor, which determines the pharmacokinetics and pharmacological eŠects of drugs. Hence, it is one of the most important areas of investigations in drug pharmacokinetics research. In fact, a large number of papers, including some reviews [1] [2] [3] have been published so far. While drug binding to plasma wasˆrst considered to represent a rather unspeciˆc physicochemical phenomenon, similar to the adsorption of small molecules to charcoal or similar compounds, accumulated evidence indicates that drug binding to albumin and to a1-acid glycoprotein (AGP) at low molar drug W protein ratios occurs at only a very few ligand binding sites of both proteins, respectively. 4, 5) Therefore, a knowledge of the properties of these drug binding sites has become an important issue for understanding pharmacokinetically relevant binding phenomena such as displacement reactions between diŠerent drugs and the dramatically altered plasma protein binding of some drugs during several disease states as well. 6, 7) Some general properties of important drug binding sites of human serum albumin (HSA) and AGP have been reviewed. 8, 9) However, the detailed characteristics of the binding sites on HSA and AGP molecules are not yet clear.
Thus, the author initiated research on drug-plasma protein binding in order to investigate the factors that govern the binding speciˆcity of HSA and AGP after his appointment as a professor of biopharmaceutics laboratory in 1983. Since then his research has been directed to biopharmaceutical issues, and has employed various biophysical and biochemical analytical methods such as spectrophotometry and protein engineering to investigate structural and functional aspects of HSA and AGP. He successfully used ‰uorescent probes to discover new ligand binding sites on major plasma proteins such as HSA. Subsequently, a topology analysis of the drug binding site on HSA was carried out using various methods, including spectroscopy, QSAR, photoa‹nity labeling, and site directed mutagenesis techniques. On the other hand, a characterization of the drug binding sites on AGP, which is known to interact with mainly basic drugs, has also been completed.
This article describes the some recentˆndings related to the mapping of drug binding sites on HSA, drugplasma protein binding in certain disease states, the possible utility of HSA in clinical applications, and the drug-binding properties of AGP.
Drug Binding Sites of HSA
HSA contains 585 amino acids and has a molecular mass of 66,500 Da. According to an X-ray crystallographic analysis of HSA and its recombinant version (rHSA), the polypeptide chain forms a heart-shaped conformation with the approximate dimension of 80× 80×80×30 Å and about 67z of it consists of a-helices, but no b-sheet is evident (Fig. 1) . X-ray diŠraction has also shown that the protein has three homologous domains (I-III), each of which is comprised of two subdomains (A and B). [10] [11] [12] HSA interacts reversibly with a broad spectrum of therapeutic agents. Typically, drugs bind to one or a very few high-a‹nity sites with typical association constants in the range of 10 4 -10 6 M -1 . The pioneering work of Sudlow et al., 13) based on the displacement of ‰uorescent probes, revealed that most drugs bind with a high a‹nity to one of two sites, referred to as site I and site II.
Typical site I ligands appear to be dicarboxylic acids and W or bulky heterocyclic molecules with a negative charge localized in the middle of the molecule. Site I probes include warfarin, 5-dimethylaminonaphthalene-1-sulfonamide (DNSA), dansylamide, dansyl-L-glutamine, dansyl-L-asparagine, dansyl-L-lysine and n-butyl p-aminobenzoate. Site I appears to be capacious and ‰exible and to contain a large number of individual ligand-binding sites that sometimes are independent of each other but in other cases, mutually in‰uence one another. 14) Ligands as large as bilirubin can be bound, and the independent binding of two diŠerent compounds to the site can occur. The fact that ligands with very diŠerent chemical structures bind to the region with high a‹nity indicates that the site is adaptable. Mutual interactions between bound ligands have been observed and this can be attributed to partially overlapping binding sites, or conformational changes in the albumin molecule (allosteric eŠect or anti-cooperativity). Singleresidue mutations in this region of albumin have a signiˆcant eŠect on the conformational and thermal stability of the protein, much more than mutations in site II. 15) Site I is formed as a pocket in subdomain IIA and involves the lone tryptophan of the protein (Trp214). 16) The inside wall of the pocket is formed by hydrophobic side chains, whereas the entrance to the pocket is surrounded by positively charged residues. Both residues contribute positively (e.g., Trp214 and Arg218) and residues that contribute negatively (e.g., Lys199 and His242) to the binding have been identiˆed in the higha‹nity binding of ligands such as warfarin.
Ligands that bind to site II (also called the indolebenzodiazepine site) are often aromatic carboxylic acids with a negatively charged acidic group at one end of the molecule that is separate from a hydrophobic center. Dansylsarcosine, dansyl-L-proline, dansylglycine, and 7-alkylaminocoumarin-4-acetic acids all function as site II probes. Site II seems to be smaller, or more narrow, than site I, because no large ligands apparently bind to it. It also appears to be less ‰exible, because binding often is strongly aŠected by stereoselectivity. Furthermore, the substitution of ligands with a relatively small group strongly in‰uences the binding. Site II is a pocket that is formed in subdomain IIIA principally the same way as site I. Among the individual amino acid residues of this subdomain, Arg410 and Tyr411 are usually assumed to be important. 17) On the basis of our mutagenesis data, we propose a new screening method, using mutant HSA, for the rapid identiˆcation of primary drug binding sites. The mutant used in such an approach must not in‰uence the binding capability of HSA at binding sites other than the one in which the mutation has taken place. Figure 2 outlines such a method using site II and the double-residue mutant R410 A W Y411A as an illustrative example.
Bhattacharya et al. 19) reported on the high-resolution crystal structures of rHSA with propofol or halothane. Propofol binds in subdomains IIIA (site II) and IIIB, with the former site having the highest a‹nity. It is probable that the latter site most also binds anions of long-chain fatty acids with a high a‹nity. In contrast, three primary sites were found for halothane, one in subdomain IIIA (site II) and two in a solvent-exposed trough at the outside interface between subdomains IIA and IIB. EckenhoŠ et al., 20) using solubilized HSA and rHSA mutants, observed that halothane, iso‰urane, and 1-chloro-1,2,2-tri‰uorocyclobutane bind primarily in the interdomain cleft between sites IA and IIA, where Trp214, an important binding residue, is located. However, the binding of anesthetics to site II was also evident.
The cysteine residue at position 34 in subdomain IA is located in a crevice on the surface of the protein and does not participate in any disulˆde bridges. Mercaptalbumin and probably also part of albumin forming mixed disulˆdes are able to bind nitric oxide and metal ions such as Ag, Hg, and Au as well as homocysteine and several drugs. Included among the latter are bucillamine derivatives, aurothiomalate, auranoˆn, D-penicillamine, captopril, ethacrynate, and cisplatin. [21] [22] [23] Covalent interaction between thiol-containing drugs and Cys34 of albumin usually also takes place in vivo, for example, N-acetyl-L-cysteine, D-penicillamine, captopril, meso-2, 3-dimercaptosuccinate and SA3786 (a bucillamine derivative). [24] [25] [26] Interestingly, the reactivity in patient sera is much higher than that found in albumin solutions and in sera from healthy volunteers. 27) Although serum albumins are highly homologous, in terms of amino acid sequence (about 80z between human and other mammalian species), the drug binding properties diŠer considerably among the species. As a result, species diŠerences with respect to drug binding to serum albumins have been examined extensively. 28, 29) However, since these studies were not investigated systematically in terms of drug binding sites, the issue of whether or not these are speciˆc drug binding sites on serum albumins is not clear, nor is the issue of the nature of such sites. For the purpose of obtaining additional information, we attempted to identify drug binding sites on diŠerent albumins using typical site I binding drugs on HSA, as well as site II of HSA. Human albumin site I appears to exist in rabbit and rat albumins, but not in the bovine and, especially not in dog albumin. However, bovine, rabbit and rat albumins lack binding sites for diazepam, and these are diŠerent from human albumin. Interestingly, the architecture of site II on dog albumin is quite similar to human albumin, although dog albumin lacks some of the important structure of site I (Fig. 3) .
30)
The three recombinant domains (domain I, II, III) of HSA were recently expressed using Pichia pastoris and were puriˆed in our laboratory. The ligand binding ability for these domains was then examined. Interestingly, all domains show a much lower ligand ability compared with rHSA, indicating the importance of interdomain interactions for maintaining the structural stability of ligand binding sites. 31) Displacement and Drug-drug Interactions on HSA In addition to competitive binding, drugs as well as other ligands can in‰uence the simultaneous binding of another drug by electrostatic eŠects and W or bindinginduced conformational changes in the protein. 32) Drug metabolites can also bind to albumin with a high a‹nity. The formation of acyl glucuronides is a major metabolic pathway for many compounds with a carboxylic acid function. This type of metabolite is a reactive electrophilic species and can therefore, in addition to participate in reversible binding, react covalently with HSA both in vitro and in vivo. Among the drugs that become glucuronidated and interact covalently with HSA are furosemide, salicylic acid, gemˆbrozil, cloˆbric acid, fenoˆbric acid and nonsteroidal A mechanism for overcoming the diuretic resistance to furosemide using drug displacement on albumin antiin‰ammatory drugs like tolmetin, benoxaprofen, zomepirac, beclobric acid, ibuprofen, ibufenac, suprofen, ketoprofen and di‰unisal. [33] [34] [35] [36] [37] Stereoselectivity was observed for, e.g., carprofen, fenoprofen, and naproxen 33, 38) ; in all cases the R-forms exhibited the highest covalent binding. Photoactivated naproxen and frusemide, as well as photoactivated frusemide glucuronide, also bind covalently to HSA. 34) Drug binding can be modulated by the simultaneous binding of endogenous compounds. Anions of longchain fatty acids can bind at low ligand-to-protein molar ratios, most probably allosterically, and diminish the binding of S-and R-thiamylal to site II. 39) The eŠect on etodolac binding is dependent on the stereochemistry of the drug, because binding of the (R)-form is increased, whereas the binding of the (S)-form was decreased. 40) At higher relative concentrations, fatty acid anions often displace site II drugs by competition.
Alterations in the binding of a drug to HSA may lead to a change in the pharmacokinetic properties of the drugs. This risk is especially relevant if two or more drugs compete for the some high-a‹nity binding site. However, in certain cases, the increase in unbound drug concentrations is much less than would be expected, because a major portion of the displaced drug rebinds at another site (secondary site). For example, most of the carprofen and diclofenac that have been competitively displaced from site II (primary site) by ibuprofen becomes quantitatively rebound at site I (secondary site) 41, 42) ; and the eŠect is stereospeciˆc. 41) Drug-drug interactions at the protein-binding level are usually regarded as problematic secondary eŠects. However, such interactions can also be useful for therapeutic purposes. For example, an attenuated response to diuretics is frequently observed in patients with the nephrotic syndrome 43) and one of the possible contributors to diuretic resistance can be due to the binding of a drug to HSA in the urine. 44) This suggests that compounds that inhibit the binding of furosemide can normalize the natriuretic eŠects of drug in the renal tubules. For assess this, we examined the inhibitory eŠect of bucolome on the binding of furosemide to protein in vitro and in vivo, because bucolome has the following properties: 1) it is a potent inhibitor of the binding of furosemide to protein in the urine; 2) when administered in large doses, its plasma concentration reaches high levels; 3) it is excreted mainly via the urine; and 4) it should be highly safe and suitable for repeated administration. The results obtained clearly suggest that bucolome has a potent inhibitory eŠect on the protein binding of furosemide to protein in the urine and can partially restore the diuretic response of furosemide in patients with the nephrotic syndrome by increasing the free fraction of furosemide at the site of action (Fig. 4) . 45) Drug displacement can also be useful in nonpathological conditions. Technetium-99m-labeled mercaptoacetylglycylglycylglycin binds strongly to albumin but it is displaced by coadministered bucolome leading to a higher unbound concentration, thereby making it more useful for renal scintigraphy.
46) The same study showed that 6-methoxy-2-naphthylacetate (a major metabolite of nabumetone), by principally the same mechanism, renders N-isopropyl-p-[
123 I]iodoamphetamine more suitable for cerebral imaging.
Drug-albumin Binding in Disease States
The concentration or the properties of serum albumin are altered in a variety of disease states. Such changes decrease drug-albumin interactions and in‰uence the fate of albumin-bound drugs in the body. It seems certain that the extent of drug-albumin interactions in patients with liver disease always decrease with serum albumin concentration. 6, 47) The binding of many drugs to albumin is decreased in patients with acute of chronic renal failure or nephrosis. 6, 48) The increase in the free drug fraction in the serum of patients with renal disease is correlated with the degree of hypoalbuminemia, but this does not fully explained the issue. Other factors that may explain the decreased interaction of drugs with albumin in renal failure include conformational changes in the albumin molecule, thus decreasing its drug-binding capacity or the accumulation of endogenous substances such as free fatty acids or uremic toxins that compete with drugs for the binding site on albumin. To data, the albumin binding of uremic toxins such as indoxyl sulfate (IS), indole acetate (IA), hippuric acid (HA), and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) to albumin has been reported in human serum, and these compounds accumulate in uremic serum to levels of up to 202, 101, 883 and 370 mmol W L, respectively. 49) These compounds are largely responsible for the impaired binding of many drugs. To elucidate the mechanism of defective drug binding induced by uremic toxins, it is necessary to examine the relationship between drug and uremic toxin-binding sites. Uremic toxins with an indole ring and HA primarily bind to site II, which is located in subdomain IIA of the HSA structure, whereas the location of the CMPF-binding site is within specialized entities in subdomain IIA, corresponding to site I. 50) The reduced binding in uremic patients may be explained by the eŠect of a combination of direct and cascade eŠects of fatty acids and uremic toxins that result in a signiˆcant inhibition in drug binding in serum (Fig. 5) . 51) If albumin is regarded as an anion transport system then substances that interfere with binding may also be able to inhibit other anion transport processes. This hypothesis is supported by evidence that CMPF inhibits the uptake of p-aminohippuric acid in rat kidney slices. Very recently, we investigated the transporters responsible for the renal uptake of uremic toxins. Both OAT1 and OAT3 contribute almost equally to the uptake of IS. OAT3 mainly accounts for CMPF uptake by the kidney, while OAT1 mainly accounts for IA and HA uptake. [52] [53] [54] [55] It is known that the covalent modiˆcation of protein has a great in‰uence on its conformational and functional properties. In fact, the decreased drug binding that is observed in diabetes, appears to depend on the extent of protein glycation and fatty acid concentration.
56) Interestingly, we recently found that advanced glycation end product albumins, produced by reacting albumin with glucose or reducing sugar are cleared from the kidney by scavenger receptor A-mediated endocytic uptake by mesangial cells.
57)
Extracorporeal Clearance using HSA Albumin can be used to clear the body of certain endogenous toxins. Among these are bilirubin, bile acids, and uremic toxins. Toxins are usually removed from the patient by hemodialysis, but the treatment frequently has only a minor eŠect. Recently, this approach has been improved by the use of thinner dialysis membranes with larger pore sizes and by adding albumin to the dialysate. In this method, albumin can be regenerated online by passing the dialysate through a charcoal column. 58) Another albumin-based extracorporeal detoxiˆer that has been developed recently is the molecular adsorbent recirculating system (MARS). MARS is a cell-free, liver assistance method for the selective removal of albumin-binding substances. 59) It also enables the removal of excess water and watersoluble substances via an inbuilt dialysis step. Technically, MARS is a modiˆed and expanded dialysis system using an albumin-containing dialysate that is recirculated and regenerated online by dialysis against a bicarbonate-buŠered solution, followed by passage through charcoal and anion-exchanger columns. This method of removing albumin-binding toxins and water-soluble substances was found to result in a decrease in hepatic encephalopathy, an increase in the mean arterial pressure, and in improvement in kidney and liver function. 60, 61) Albumin dialysis in the form of a routine continuous veno-venous hemodiaˆltration using a 44 g W l albumin-containing dialysate and a slow dialysate ‰ow rate (1-2 l W h) has been shown to be eŠective in the treatment of fulminant Wilson disease, resulting in the removal of protein-binding toxins such as copper and bilirubin. 62) Endotoxins such as lipopolysaccharides and cytokines, and possibly other toxins as well, can be removed by passing blood through columns that contain immobilized albumin.
The above-mentioned methods, or modiˆcations thereof, can also be used in the treatment of drugoverdoses. Charcoal hemoperfusion is a very eŠective extracorporeal treatment in cases of drug overdose.
63) It is generally accepted that charcoal hemoperfusion can not remove drugs that are largely bound to plasma proteins. We recently attempted to deˆne a guideline based on the percentage of a drug that binds to protein for use in the treatment of drug-overdose cases. The relationship between the extraction e‹ciencies of a charcoal column and the plasma protein binding percentage of the drugs showed that drugs bound at levels of 90-95z, or less, could be eŠectively removed from the blood (Fig. 6) . 64) However, the more tightly bound drugs were only partially removed. Our results show that, in addition to the volume of distribution, the degree of plasma protein binding can also be used as determinant for clearance by hemoperfusion, especially in the case of drugs with a binding percentage above 95z. The clinical decision as to whether to initiate hemoperfusion or not should not be made by taking only the volume of distribution of drug into consideration. The protein binding percentage is useful information in the choice of a suitable treatment for overdose patients.
Oxidized Albumin as a Biomarker in Uremic Patients
Recently, increasing attention has been paid to albumin as a biomarker of oxidative stress among biological substances because this molecule represents the major and predominant circulating antioxidant in plasma for continuous oxidative stress. The accessibility of plasma proteins for sampling, the relatively long plasma halflives of many proteins, and the well-deˆned biochemical pathways that lead to protein oxidation can be used to detect more speciˆc pathways of oxidative stress than plasma lipids. For example, oxidation of the amino acyl side chains of amino acids in proteins is an attractive biomarker of oxidative reactions because of the high speciˆcity of the end products for speciˆc oxidation pathways. In particular, detection of oxidized cysteine residues currently constitutes the most sensitive and speciˆc means available for detecting end products of speciˆc oxidative pathways. 65) Recent studies of some investigators have clearly demonstrated high levels of thiol group oxidation as well as carbonyl formation in plasma proteins from patients with uremia. 66) Since albumin is the most abundant protein in plasma, it could play a major role as an antioxidant in plasma at least with respect to thiol oxidation and carbonyl formation. Albumin is a mixture of mercaptalbumin (HMA; reduced form) and nonmercaptalbumin (HNA; oxidized form) i.e. a protein redox couple in serum. 67) HMA contains one highly reactive sulfhydryl group at position 34 (Cys34), while other serum proteins contain few or none. 10) HNA is composed of at least three types of molecules. The major HNA component is a mixed disulˆde with cysteine or glutathione (HNA(Cys) or HNA(Glut)). The other is a more highly oxidized product than the mixed disulˆde, such as sulfenic (-SOH), sulˆnic (-SO2H) and sulfonic (-SO3H) states (HNA(Oxi)), the proportions of which are extremely small in extracellular ‰uids.
68) The highperformance liquid chromatographic (HPLC) analysis 67) and is used for the determination of the redox state for various pathophysiological conditions. 69, 70) In this sense, one of the important physiological functions of serum albumin could be to participate in the maintenance of a constant redox potential in the extracellular milieu. We also recently demonstrated that the HPLC analysis of serum albumin represents a potentially useful method for the quantitative and qualitative evaluation of oxidative stress in chronic HD patients and the results strongly suggest the possibility that oxidative stress, generated by the iv administration of iron IVIR, enhances the oxidation of albumin in such patients (Fig. 7) . 70) In addition to oxidized cysteine residues, other important amino acyl groups subject to oxidation include tyrosine, amino groups (such as Lys), and alcohol groups. In particular, the oxidation of Tyr residues leads to the formation of 3-chlorotyrosine, 3-nitrotyrosine, or dityrosine. 65) Hemelliferb et al. recently demonstrated that plasma proteins from uremic patients contain elevated levels of 3-chlorotyrosine, but not 3-nitrotyrosine or dityrosine. Since this product (3-chlorotyrosine) is a speciˆc product of the myeloperoxidase catalyzed reaction, it further suggests a speciˆc and important role for phagocyte-initiated oxidative reactions as the cause of excess oxidative stress in uremia. 71) Witko-Sarsat et al. also demonstrated elevated levels of advanced oxidative protein products (AOPP) in plasma from uremic patients.
72) The contents of AOPP lead to the formation of dityrosine and account for almost all of the excess oxidation of albumin in uremic patients. Further, the contents of AOPP are good correlated with the levels of HNA. Collectively, these studies suggest that the oxidation of albumin in uremia mainly leads to the oxidation of cysteine and tyrosine residues and that these residues, when present on albumin, are useful biomarkers for the quantitative and qualitative evaluation of oxidative stress.
Characteristics of Drug-biding Site on AGP
AGP, a member of the lipocalin family, is a 40 kDa protein consisting of 183 amino acids with two disulˆde bonds andˆve carbohydrate chains (Fig. 8) .
73) Although the three-dimensional structure is still unknown, circular dichroism (CD) measurements and molecular modeling indicate that this protein, in aqueous solution, is mostly made up of b-sheets. 74, 75) The interaction of many drugs with AGP have been reported, whereas the binding site of AGP has not been clariˆed.
AGP is one of the most glycosylated proteins, to extent of 40z of its total mass. The biological role of the oligosaccharide moiety was found to be exhibited in acute phase events, 76) whereas the moiety appears not to be involved in the binding properties of AGP. Friedman et al. found that sialic acids attached to oligosaccharides of AGP had no eŠect on its binding capacity and structural properties. 77) Other reports 73, 78) that the removal of oligosaccharides from AGP has no eŠect on its structural properties also supports the theory that oligosaccharides of AGP are not associated with the binding properties of the protein. In addition, we established the AGP expression system in yeast, Pichia pastoris, for thê rst time. 79) The oligosaccharides of glycoprotein derived from yeast are the high mannose type. Recombinant AGP has almost the same binding capacity as human plasma derived AGP, but the type of oligosaccharide are diŠerent. These results strongly suggest that drug binding properties do not depend on the type and presence of oligosaccharide.
We previously classiˆed the drug-binding sites on AGP by displacement experiments using ‰uorescent probes. 80) Basic drugs not only e‹ciently displaced basic probes but acidic probes as well. On the other hand, acidic probes were displaced by acidic drugs such as phenylbutazone and sulfadimethoxine, which had no eŠect on most of the basic probes. This contradiction suggests that basic drugs do not completely share a binding site with acidic drugs. These displacement data suggest that the binding sites on AGP are not completely separated but are signiˆcantly overlapped and in‰uence one another. In addition, we found that dicumarol-AGP and dicumarol-AGP-protriptyline form a 1:1 binary complex and a 1:1:1 ternary complex respectively, as evidenced by CD titration and equilibrium dialysis experiments. 81, 82) Moreover, the binding experiments using dicumarol and chlorpromazine showed that the binding sites for basic and acidic drugs overlapped each other. Using chemically modiˆed AGP, it was found that Trp, Tyr and Lys residues are involved in the dicumarol binding site, and that Trp and Lys residues are involved in chlorpromazine binding site.
7b-Hydroxystaurosporine (UCN-01) is a protein kinase inhibitor anticancer drug that is currently undergoing phase II clinical trials. 83, 84) The low distribution volumes and systemic clearance of UCN-01 in human patients was found to be due to its extraordinarily high a‹nity binding to AGP. 85, 86) We recently have reported on the binding properties of this drug to AGP.
87) The binding a‹nity of staurosporine, as well as UCN-02, 7a-hydroxystaurosporine, to AGP was lower than that of UCN-01 by 20-and 100-fold respectively. The percentage of UCN-01 that binds to AGP was low in an acidic pH region but increased with increasing pH, reaching a maximum at pH 7.4. The binding of UCN-01 to desialylated AGP was comparable to that of AGP. Chemical modiˆcation of the His, Lys, Trp, and Tyr residues caused a decrease in the percentage of bound UCN-01. Trp-modiˆed AGP showed the largest decrease in binding. This result is consistent with thê nding for the binding sites of dicumarol and chlorpromazine. Moreover, tryptophanyl ‰uorescence quenching results indicate that Trp residues play a prominent role in the binding of UCN-01 to AGP. These results indicate that a substituent at the C-7 position of UCN-01 appeared to in‰uence the binding speciˆcity of the drug, and Trp residues in AGP play a prominent role in the high a‹nity binding of UCN-01 to AGP. In addition, we photolabeled AGP with [
3 H]UCN -01 without further chemical modiˆcation. 88 reported that diethylpyrocarbonate (DEPC) speciˆ-cally modiˆed His97 and 100, as evidenced by highperformance liquid chromatography electrospray ionization-mass spectrometry and matrix-assisted laser desorption W ionization time-of-‰ight-mass spectrometry. 90) Interestingly, the DEPC-modiˆcation to His97 was inhibited in the presence of warfarin. This indicates that His97 is involved in the binding site for acidic drugs. These inconsistentˆndings indicate that AGP contains a wide drug-binding region for basic, acidic and neutral drugs (Fig. 9) . Thus, more attention should be paid to the characterization of drug binding sites on AGP.
Moreover, both dog and bovine AGP have a basic ligand binding site and a steroid hormone binding site, which signiˆcantly overlap and aŠect one another. However, dog and bovine AGPs do not contain an acidic ligand binding region. 91) The results of ‰uores-cence experiments indicate that the hydrophobic nature of the ligand binding pockets on the human, dog and bovine AGP are similar, but that their microviscosities are markedly diŠerent.
AGP is a mixture of at least two genetic variants: the A variant and the F1 and W or S variant or variants, which are encoded by two diŠerent genes. Herve et al. reported on the fractionation of the genetic variants of AGP in the native form by chromatography on an immobilized copper (II) a‹nity adsorbent, and determined the a‹nities of the two main gene products of AGP (i.e., the A variant and a mixture of the F1 and S variants) for 35 chemically diverse drugs and reported meaningful 3D-QSARs for each binding site. 92) A‹nities were obtained by displacement experiments, leading to qualitative information concerning the binding sites. In particular, drugs that bind selectively to the A variant displayed some common structural features, but this was not seen for the F1*S variants. In addition, Herve et al found changes in the expression and microheterogeneity of the genetic variants of AGP in malignant mesothelioma. 93) This suggests that ratio of the F1*S to the A variants can vary under certain disease conditions, and that the drug-binding selectivity of variants is important factor for monitoring the AGPbinding drugs. Moreover, Jolliet-Riant et al. found that AGP binding decreases brain drug transfer when the A variant is mainly and almost exclusively involved in the binding. 94) On the contrary, the entire fraction of the tested drugs when bound exclusively or partly to the F1*S variant is available for transfer to the brain. This indicates the importance of understanding the drug-binding selectivity of AGP-binding drugs to variants.
AGP-mediated Drug Transport
The hypothesis that the membrane transport of a drug depends on the non-bound drug concentration is widely accepted. However, because this hypothesis does not fully explain the mechanism of uptake of some AGP-binding drugs, a protein-mediated uptake system has been proposed. In such a system, structural changes in the protein, due to interaction with the membrane surface decreases the drug-binding capacity. [95] [96] [97] Recent ESR spectroscopicˆndings show that the structure of HSA changes after it interacts with the surface of hepatocytes supports this proposed system. 98) It was recently reported that AGP binds to the vascular endothelial cell surface and then causes transcytosis across the cell without passing the intercellular junction. 94) Andersen detected AGP on the surface of human monocytes, granulocytes, and lymphocytes using ‰uorescent electron microscopy. 100,101) Maeda et al. found that AGP binds to the membrane surface of erythrocyte and stabilizes it. 102) Other studies of interaction of AGP with vesicles 103) and liposomes 104) also support the conclusion that AGP interacts with the membrane in circulation and may in‰uence intracellular events.
We previously examined the structural properties and ligand-binding capacity of AGP in interactions with reverse micelles, and detailed information was obtained by comparing several diŠerent states of AGP. 105) Interaction with reverse micelles induced a unique conformational transition (b-sheet to a-helices) in AGP and decreased the binding capacity for the basic drug, chlorpromazine and the steroid hormone, progesterone to AGP. These structural conformations are very similar to those observed under conditions of acidity and high ionic strength (pH 2.0, 1.5 M NaCl). This structure seems to be an intermediate between the native state and the denatured state, possibly a molten globule. The present results suggest that, when AGP interacts with a biomembrane, it undergoes a structural transition to a unique structure that is diŠerent from both the native and denatured states and has a reduced ligandbinding capacity (Fig. 10) . In addition, we investigated the structural properties and ligand-binding capacity of AGP under mild acidic conditions and its interactions with liposomes prepared from neutral or anionic lipids and the neutral drug, progesterone. 106) Interestingly, AGP had a unique structure at pH 4.5, at which the tertiary structure changed, whereas the secondary struc-ture remained intact. Furthermore, the binding capacity of AGP for progesterone did not change signiˆcantly under these conditions. It was also observed that AGP was strongly bound to the anionic membrane at pH 4.5, forming an a-helix-rich structure from the original b-sheet-rich structure, which signiˆcantly decreased the binding capacity of AGP for progesterone. The structural transitions as well as the membrane binding were suppressed by adding NaCl. These results indicate that AGP has a unique structure on the membrane surface under mildly acidic conditions. The conformational change induces the molecule to bind to the membrane, aided by electrostatic interactions, and AGP subsequently assumes a predominantly a-helical conformation. Moreover, we found that alkanols, diols, and halogenols all induce such a conformational change. 107) An increase in the length and bulkiness of the hydrocarbon group and the presence of a halogen atom promoted this conversion, whereas the presence of a hydroxyl group inhibited it. Moreover, the eŠect was dependent on the hydrophobic and electrostatic properties of the alcohols. These results indicate that, in a membrane environment, hydrophobic and electrostatic factors cooperatively induce the transition of AGP from a b-sheet to an a-helix.
Development of Fluorescence Reagent for AGP Determination in Plasma
The human AGP level in plasma is between about 50 and 100 mg W 100 mL. The AGP level can increase considerably in certain diseases, the use of drugs and in pregnancy. 9, 108, 109) AGP is commonly measured by a single immunodiŠusion (SRID) method.
We attempted to develop a ‰uorescent probe that is superior to conventional ones (8-anilino-1-naphthalenesulfonate and auramine O) for use in the study of the drug-binding sites on AGP.
110) It was found that quinaldine red (QR) strongly bound to AGP and had an enhanced ‰uorescence in the presence of AGP at a longer wavelength, although QR was rarely ‰uorescent in an aqueous or albumin solution. The binding parameters of QR to AGP were K: 1.3×10 6 M -1 and n: 0.9, using the ‰uorometric titration method. The ‰uorescence of QR in the AGP solution, however, was markedly quenched in the presence of basic drugs, indicating that these drugs competitively displaced QR from its binding site; the results were in good agreement with those in the literature. The good relationship between binding a‹nities and partition coe‹cients suggest that hydrophobic forces are involved in the binding of basic drugs to AGP. Moreover, the polarity of the binding site of AGP, as estimated from the relationship between the emission maximum of QR and Z values was 70, which corresponds to the same Z value of acetonitrile. These results distinguish QR from other conventional AGP probes as a better ‰uorescent probe for developing an understanding of drug-AGP interaction and the characterization of binding sites on AGP in more detail.
AGP is an acute phase protein, the plasma level of which can be used as a diagnostic and prognostic aid during clinical therapy. This has implications for the monitoring of the free fractions of basic drugs during clinical therapy. Therefore, we examined diŠerent ‰uorescent probes that might be suitable for the ‰uoro-metric determination of AGP in serum. 111) Taking advantage of the enhanced ‰uorescence of QR in the presence of AGP, we developed a direct method for the determination of serum AGP without the need to remove other serum proteins, such as albumin. The AGP concentrations in sera of healthy volunteers and patients were correlated well with results obtained using the conventional single radial immunodiŠusion (SRID) method (r＝0.93, slope＝1). The new method is faster and has a larger analytical concentration range than the SRID method. This method can also be used to determine AGP in serum for diagnosis and prognosis aid and it can serve to monitor AGP serum concentrations for the pharmacokinetic evaluation of basic drugs.
Conclusion
This review mainly summarizes recentˆndings including our data regarding drug-plasma protein interactions. Recent work with approaches such as the use of recombinant mutants and structural biology has proved much new information concerning the structural and functional characteristics of HSA and AGP. Advances in current DNA recombinant technologies enable the preparation of albumin and AGP with multifunctional properties. These proteins could possibly be useful as drug delivery system (DDS) carriers although the application of plasma protein to DDS has not been discussed because of space considerations. Plasma protein science including drug-binding interactions is entering a new phase of development.
